Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

S. Giebel, DI. Marks, N. Boissel, F. Baron, S. Chiaretti, F. Ciceri, JJ. Cornelissen, M. Doubek, J. Esteve, A. Fielding, R. Foa, NC. Gorin, N. Gökbuget, H. Hallböök, D. Hoelzer, E. Paravichnikova, JM. Ribera, B. Savani, AW. Rijneveld, C. Schmid,...

. 2019 ; 54 (6) : 798-809. [pub] 20181101

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025826
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 1997-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 30385870
DOI 10.1038/s41409-018-0373-4
Knihovny.cz E-zdroje

Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the stratification systems vary among study groups. Inadequate response at the level of minimal residual disease is the most commonly accepted factor indicating the need for alloHSCT. In this consensus paper on behalf of the European Working Group for Adult Acute Lymphoblastic Leukemia and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize available evidence and reflect current clinical practice in major European study groups regarding both indications for HSCT and particular aspects of the procedure including the choice of donor, source of stem cells and conditioning. Finally, we propose recommendations for daily clinical practice as well as for planning of prospective trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025826
003      
CZ-PrNML
005      
20240528153437.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-018-0373-4 $2 doi
035    __
$a (PubMed)30385870
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Giebel, Sebastian $u Maria Sklodowska-Curie Institute-Cancer Center, Gliwice Branch, Gliwice, Poland. sgiebel@io.gliwice.pl.
245    10
$a Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) / $c S. Giebel, DI. Marks, N. Boissel, F. Baron, S. Chiaretti, F. Ciceri, JJ. Cornelissen, M. Doubek, J. Esteve, A. Fielding, R. Foa, NC. Gorin, N. Gökbuget, H. Hallböök, D. Hoelzer, E. Paravichnikova, JM. Ribera, B. Savani, AW. Rijneveld, C. Schmid, U. Wartiovaara-Kautto, M. Mohty, A. Nagler, H. Dombret,
520    9_
$a Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the stratification systems vary among study groups. Inadequate response at the level of minimal residual disease is the most commonly accepted factor indicating the need for alloHSCT. In this consensus paper on behalf of the European Working Group for Adult Acute Lymphoblastic Leukemia and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize available evidence and reflect current clinical practice in major European study groups regarding both indications for HSCT and particular aspects of the procedure including the choice of donor, source of stem cells and conditioning. Finally, we propose recommendations for daily clinical practice as well as for planning of prospective trials.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a transplantace hematopoetických kmenových buněk $x metody $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a akutní lymfatická leukemie $x terapie $7 D054198
650    _2
$a prospektivní studie $7 D011446
650    _2
$a indukce remise $7 D012074
650    _2
$a příprava pacienta k transplantaci $x metody $7 D019172
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Marks, David I $u University Hospitals Bristol National Health Service Foundation Trust, Bristol, UK.
700    1_
$a Boissel, Nicolas $u Hopital St. Louis, Paris, France.
700    1_
$a Baron, Frederic $u CHU Sart-Tilman, University of Liege, Liege, Belgium.
700    1_
$a Chiaretti, Sabina $u Sapienza University, Rome, Italy.
700    1_
$a Ciceri, Fabio $u San Raffaele Scientific Institute, Milan, Italy.
700    1_
$a Cornelissen, Jan J $u Erasmus MC Cancer Institute University Medical Center, Rotterdam, The Netherlands.
700    1_
$a Doubek, Michael $u University Hospital, Brno, Czechia.
700    1_
$a Esteve, Jordi $u IDIBAPS, Hospital Clinic, Barcelona, Spain.
700    1_
$a Fielding, Adele $u North London Cancer Network, Univ. College London Hosp, London, UK.
700    1_
$a Foa, Robin $u Sapienza University, Rome, Italy. $7 xx0317383
700    1_
$a Gorin, Norbert-Claude $u EBMT Acute Leukemia Working Party Office, Paris, France. Hospital Saint-Antoine, Paris, France.
700    1_
$a Gökbuget, Nicola $u Maria Sklodowska-Curie Institute-Cancer Center, Gliwice Branch, Gliwice, Poland. Hopital St. Louis, Paris, France.
700    1_
$a Hallböök, Helene $u Uppsala University, Uppsala, Sweden.
700    1_
$a Hoelzer, Dieter $u University Hospital, Goethe University, Frankfurt, Germany.
700    1_
$a Paravichnikova, Elena $u FGBU Hematology Research Center, Russia Federation Ministry of Public Health, Moscow, Russia.
700    1_
$a Ribera, Josep-Maria $u ICO-Hospital Germans Trias I Pujol, Jose Carreras Research Institute, Badalona, Spain.
700    1_
$a Savani, Bipin N. $u Vanderbilt University Medical Center, Nashville, USA. $7 xx0317726
700    1_
$a Rijneveld, Anita W $u Erasmus MC Cancer Institute University Medical Center, Rotterdam, The Netherlands.
700    1_
$a Schmid, Christoph $u Klinikum Augsburg, Ludwig-Maximilians-Universitaet, Munich-Augsburg, Germany.
700    1_
$a Wartiovaara-Kautto, Ulla $u Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Mohty, Mohamad $u North London Cancer Network, Univ. College London Hosp, London, UK. EBMT Acute Leukemia Working Party Office, Paris, France. $7 xx0317729
700    1_
$a Nagler, Arnon $u North London Cancer Network, Univ. College London Hosp, London, UK. Chaim Sheba Medical Center, Tel-Hashomer, Israel.
700    1_
$a Dombret, Hervé $u Hopital St. Louis, Paris, France. $7 xx0316388
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 54, č. 6 (2019), s. 798-809
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30385870 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20240528153434 $b ABA008
999    __
$a ok $b bmc $g 1599971 $s 1116512
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 54 $c 6 $d 798-809 $e 20181101 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace